These studies have shown that besides norepinephrine, neurotransmitters such as acetylcholine, neuropeptide Y, GABA, and others might also affect carcinogenesis and cancer progression (for review see102) and that these effects might be significantly reduced by antagonists of neurotransmitter receptors, such as propranolol. Here, NPY is linked to cancer.